Key Highlights

  • Issuance of 124,000 common shares at $6.452 per share in a private placement.
  • Proceeds allocated to working capital and general corporate needs.
  • The offering consisted of 124,000 shares of common stock, each sold at a purchase price of $6.452.

Silo Pharma, Inc. (NASDAQ: SILO) reported the successful closing of a private placement on July 10, 2026, generating gross proceeds in the vicinity of $3.5 million after the deduction of applicable fees. The capital raise was structured to combine equity issuance with a layered warrant program, thereby enhancing the company’s balance sheet while preserving flexibility for future financing activities.

Deal Structure Overview

The offering consisted of 124,000 shares of common stock, each sold at a purchase price of $6.452. In addition to the equity component, investors were granted pre‑funded warrants that collectively permit the acquisition of up to 495,965 shares at a price of $6.4519 per warrant. Complementing these were two distinct series of traditional warrants, Series A‑3 and Series A‑4, each authorizing the purchase of up to 619,965 shares.

Pricing and Ownership Constraints

The warrant framework incorporates ownership caps designed to satisfy securities regulations. No single holder may possess more than a 4.99% interest in the company after exercising any warrant, and a broader ceiling of 9.99% applies to certain allocations. Adjustments to these thresholds may be permitted up to 9.99% provided that the holder delivers a 61‑day notice to Silo Pharma.

The pre‑funded warrants can be exercised for a nominal amount of $0.0001 per share, while still adhering to the 9.99% overall ownership limitation.

Placement Agent Compensation

H.C. Wainwright & Co. LLC served as the exclusive placement agent for the transaction. Compensation to the agent consisted of a cash fee equal to 7.5% of the total gross proceeds, alongside a management fee of 1.0% of the same amount.

In addition, the agent received warrants enabling the purchase of up to 7.5% of the placed shares, equating to 46,497 common shares, each warrant carrying an exercise price of $8.065 per share.

Registration Rights Commitment

Pursuant to a registration rights agreement, Silo Pharma committed to file a resale registration statement with the SEC within 15 days of the agreement’s execution. The company pledged to use commercially reasonable efforts to secure effectiveness of the registration statement within 30 days, extending to 60 days if a full SEC review is required. This commitment facilitates the orderly resale of the securities issued in the private placement under public market conditions.

Use of Proceeds

The capital raised, approximating $3.5 million, is earmarked for working capital and other general corporate purposes. Management indicated that the influx of funds will support ongoing operational activities, provide liquidity for routine expenses, and afford strategic flexibility for future initiatives within the biopharmaceutical sector.

Industry Context

The biotech industry continues to rely on private placements as a critical financing tool, particularly for companies seeking to advance pipeline programs while avoiding dilution from larger public offerings. By coupling equity with a diversified warrant package, Silo Pharma aligns its capital strategy with prevailing market practices that balance immediate funding needs against long‑term shareholder value considerations. The inclusion of pre‑funded warrants, which allow investors to secure exposure without an upfront cash outlay, reflects a growing trend among capital‑intensive sectors seeking to attract sophisticated institutional investors.

Overall, the transaction strengthens Silo Pharma’s financial position and underscores its commitment to maintaining sufficient capital resources as it pursues its development objectives.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.